During the last session, Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s traded shares were 0.6 million, with the beta value of the company hitting 1.30. The 52-week high for the SYRS share is $7.96, that puts it down -3690.48 from that peak though still a striking 14.29% gain since the share price plummeted to a 52-week low of $0.18. The company’s market capitalization is $5.67M, and the average intraday trading volume over the past 10 days was 1.55 million shares, and the average trade volume was 9.76 million shares over the past three months.
Syros Pharmaceuticals Inc (SYRS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.33. SYRS has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it.
Syros Pharmaceuticals Inc (NASDAQ:SYRS) trade information
Syros Pharmaceuticals Inc (SYRS) registered a 2.23% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.23% in intraday trading to $0.21, hitting a weekly high. The stock’s 5-day price performance is 3.07%, and it has moved by 5.65% in 30 days. Based on these gigs, the overall price performance for the year is -96.75%. The short interest in Syros Pharmaceuticals Inc (NASDAQ:SYRS) is 1.1 million shares and it means that shorts have 0.37 day(s) to cover.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 95.8% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $5 respectively. As a result, SYRS is trading at a discount of -2280.95% off the target high and -2280.95% off the low.
Syros Pharmaceuticals Inc (SYRS) estimates and forecasts
Statistics show that Syros Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Syros Pharmaceuticals Inc (SYRS) shares have gone down -96.36% during the last six months, with a year-to-date growth rate more than the industry average at 65.53% against 16.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 21.16%. While earnings are projected to return 72.86% in 2025, the next five years will return 26.36% per annum.
SYRS Dividends
Syros Pharmaceuticals Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s Major holders
Syros Pharmaceuticals Inc insiders own 0.74% of total outstanding shares while institutional holders control 75.65%, with the float percentage being 76.22%.
Also, the Mutual Funds coming in first place with the largest holdings of Syros Pharmaceuticals Inc (SYRS) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 654.18 shares. This amounts to just over 2.44 percent of the company’s overall shares, with a $0.14 million market value. The same data shows that the other fund manager holds slightly less at 257.63, or about 0.96% of the stock, which is worth about $54438.0.
